Fintel reports that on July 21, 2025, Truist Securities initiated coverage of Alnylam Pharmaceuticals (NasdaqGS:ALNY) with a Buy recommendation. Analyst Price Forecast Suggests 6.19% Upside As of July ...

After Falling 68%, Where Will This Weight-Loss Drug Stock Be in 2 Years? History Shows Massive Gains Ahead. Yet another ...

Wells Fargo analyst Mohit Bansal maintained a Hold rating on Merck & Company yesterday and set a price target of $97.00. The company’s shares closed yesterday at $81.52. Elevate ...

Regeneron Pharmaceuticals Inc. closed 55.21% below its 52-week high of $1,211.20, which the company reached on August 27th.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the Best Non-Mega Cap NASDAQ Stocks to Buy Right Now. UBS analyst Trung Huynh raised the price target on Regeneron Pharmaceuticals, Inc. (NASDAQ ...

Oversea Chinese Banking Corp Ltd acquired a $30.17 million stake in Regeneron Pharmaceuticals during the first quarter, ...

Morgan Stanley slightly lowered its price target for Regeneron Pharmaceuticals while maintaining an overweight rating, ...

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 best debt-free stocks to invest in right now. The company ...

Analysts have recently evaluated Regeneron Pharmaceuticals and provided 12-month price targets. The average target is $769.35, accompanied by a high estimate of $975.00 and a low estimate of $547.00.

Regeneron Pharmaceuticals sees strength in Dupixent, oncology gains, and major buybacks despite setbacks. Find out why REGN ...

Fintel reports that on July 9, 2025, Piper Sandler initiated coverage of Inovio Pharmaceuticals (NasdaqCM:INO) with a ...

Analysts expect the S&P 500 to rise 7.5% over the next year, according to a recent analysis of stock price targets. Wall ...